重组人血小板生成素治疗脓毒症相关血小板减少症的效果观察

Therapeutic effects of recombinant human thrombopoietin on sepsis-associated thrombocytopenia

目的探讨重组人血小板生成素(rhTPO)治疗脓毒症相关血小板减少症的临床价值。方法利用随机数字表法将山西医科大学第二医院2016年1月至2017年12月收治的84例脓毒症相关血小板减少症患者均分为研究组和对照组,每组42例。对照组予以常规治疗,研究组在常规治疗基础上加用rhTPO,记录两组治疗期间血制品使用情况及血小板计数变化情况。结果治疗期间,研究组血小板、浓缩红细胞、新鲜冰冻血浆等血制品输注量均少于对照组(P均<0.05)。治疗前,两组血小板计数比较差异未见统计学意义(P>0.05);治疗后3、7、10d,研究组血小板计数检测值较治疗前上升幅度均优于对照组(P均<0.05)。结论应用rhTPO治疗脓毒症相关血小板减少症效果显著,有利于获得更优的血小板计数改善效果,同时能够减少血制品用量。

Objective To investigate the clinical value of recombinant human thrombopoietin (rhTPO) in the treatment of sepsis-related thrombocytopenia. Methods Eighty-four patients with sepsis-related thrombocytopenia admitted to the Second Hospital of Shanxi Medical University from January 2016 to December 2017 were evenly divided into study group and control group according to random number table method, with 42 cases in each group. Patients in control group were given routine treatment, while patients in study group were given rhTPO on the basis of routine treatment. The use of blood products and the change of platelet count during treatment were recorded. Results During the treatment period, the infusion volume of blood products such as platelets, concentrated red blood cells and fresh frozen plasma in study group was less than that in control group (P<0.05). Before treatment, there was no significant difference in platelet count between the two groups (P>0.05);the platelet count in study group increased more rapidly than that in control group 3, 7 and 10 days after treatment (P all <0.05). Conclusions The use of rhTPO in the treatment of sepsis-related thrombocytopenia is effective, which is beneficial to improvement in platelet count and reduction in blood product consumption.